Regulation des CREB-Koaktivators TORC durch β-adrenerge Signale in isolierten neonatalen Rattenkardiomyozyten

Wichmann, Helen

dc.contributor.advisor	Paul, Thomas Prof. Dr.
dc.contributor.author	Wichmann, Helen
dc.date.accessioned	2018-03-22T10:33:44Z
dc.date.available	2018-04-03T22:50:06Z
dc.date.issued	2018-03-22
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-002E-E39B-F
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-6785
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc	610	de
dc.title	Regulation des CREB-Koaktivators TORC durch β-adrenerge Signale in isolierten neonatalen Rattenkardiomyozyten	de
dc.type	doctoralThesis	de
dc.title.translated	Regulation of the CREB coactivator TORC by β-adrenergic signals in isolated neonatal rat cardiomyocytes	de
dc.contributor.referee	Zimmermann, Wolfram-Hubertus Prof. Dr.
dc.date.examination	2018-03-27
dc.description.abstracteng	TORC (transducers of regulated CREB) describes a family of transcriptional cofactors, which regulates the activation of several transcription factors in dependence on cAMP. TORC is dephosphorylated and thus activated by β-adrenergic-induced increases in cAMP and subsequent PKA and calcineurin activation. Dephosphorylated TORC translocates into the nucleus where it contributes to the CREB-dependent gene transcription. Its function and regulation has so far been demonstrated in different tissue cells. The aim of this thesis was to determine the function, activation and cellular localisation of TORC in the heart and to investigate its involvement on the pathogenesis of cardiac hypertrophy. In order to investigate whether TORC plays a role in the pathogenesis of maladaptive hypertrophy, heart tissue samples from patients with inherited and acquired myocardial heart diseases were compared to the subcellular localization of TORC1 and TORC3 using immunhistochemistry. Investigations of TORC1 and TORC3 on human hypertrophic heart tissue samples showed that TORC1 expression in the cell nucleus and cytosol is relatively stronger in acquired cardiac hypertrophy than in inherited hypertrophy, which indicates that TORC has a relevance for the pathogenesis of pathological cardiac hypertrophy. It is assumed that pathological myocardial hypertrophy is associated with an increased β1-adrenergic receptor stimulation. On the basis of publications showing that TORC is activated by cAMP signals, it was investigated whether TORC1 in cardiomyocytes can also be activated by activation of the β-adrenergic receptor. A model consisting of neonatal rat cardiomyocytes was used for this study. By treating the cardiomyocytes with the β-adrenoceptor agonist isoprenaline, the alteration of the activity state of TORC1 by a cAMP-dependent signaling pathway was investigated. The effect of isoprenaline on phosphorylated TORC1 in relation to the total amount of TORC1 was investigated in concentration-response and time-response curves and compared with the ratio of the untreated control. The state of phosphorylation, and hence the state of activity, of TORC1 was detected in the immunoblot using phosphorylation-specific antibodies. These investigations did not reveal any reproducible changes in the phosphorylation state of the TORC1-P/TORC1 ratio compared to the control, so that it could not be demonstrated that TORC1 is involved in the signal cascade of the β-adrenergic receptor. As a possible target gene of TORC1, the expression of the PGC1α mRNA was investigated using real-time PCR. However, the results of the PGC1α mRNA expression were not correlated with the TORC1 protein data.	de
dc.contributor.coReferee	Meyer, Thomas Prof. Dr.
dc.contributor.thirdReferee	Oppermann, Martin Prof. Dr.
dc.subject.ger	Isoprenalin	de
dc.subject.ger	TORC1	de
dc.subject.ger	kardiale Hypertrophie	de
dc.subject.ger	CRTC1	de
dc.subject.eng	isoprenaline	de
dc.subject.eng	TORC1	de
dc.subject.eng	cardiac hypertrophy	de
dc.subject.eng	CRTC1	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-002E-E39B-F-2
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Medizin (PPN619874732)	de
dc.description.embargoed	2018-04-03
dc.identifier.ppn	1016296436

Dateien

Name:e-Diss Helen Wichmann.pdf

Größe:1.180Mb

Format:PDF

Öffnen

Name:: e-Diss Helen Wichmann.pdf
Größe:: 1.180Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2872]

Zur Kurzanzeige